Linzess

Quick links to important sections

Linzess

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Linzess

Property Description
Active ingredient Linaclotide
Form Oral Capsule (Delayed-release)
Pharmacological class Guanylate Cyclase-C (GC-C) Agonist
Common use Gastrointestinal motility regulation
Origin Synthetic polypeptide drug

What Type of Medicine is Linzess?

Linzess (active ingredient: Linaclotide) is a prescription-only synthetic polypeptide drug classified as a Guanylate Cyclase-C (GC-C) Agonist. This classification means the medicine is a laboratory-engineered peptide compound, not a naturally occurring substance, designed to activate a specific receptor in the body. The drug maintains an established presence within the specialized gastrointestinal treatment market.

The pharmacological class of a GC-C Agonist differentiates Linzess from older agents, such as osmotic or stimulant laxatives, because it engages in a highly targeted signaling pathway within the gut lining. This mechanism results in a distinct action. Chemically, Linaclotide is a synthetic 14-amino acid peptide that acts locally within the intestinal lumen, ensuring minimal systemic absorption.

Linaclotide: Composition and General Purpose

Linzess is formulated as an oral capsule containing the single active ingredient, Linaclotide, prepared for delayed release. This composition is a key feature, as it protects the active peptide until it reaches the intestine, confirming its physical stability is essential to its therapeutic role. The drug is intended exclusively for adults, focusing its positioning on addressing mature patient populations with chronic digestive issues.

The general purpose of the medicine is to serve as a specialized gastrointestinal motility regulator. By activating the GC-C receptor, Linaclotide enhances the production of a signaling molecule which, in turn, promotes the secretion of fluid into the intestine and accelerates the movement of material through the digestive system. This mechanism also increases the threshold for colonic sensation, which is recognized for its role in potentially reducing the perception of abdominal discomfort.

Regulatory References

  1. Linaclotide Pharmacokinetics
  2. Constella (linaclotide) EPAR

What side effects are possible with Linzess?

Possible Side Effects and Safety Information

Safety information for Linzess (linaclotide) is based on data from official government regulatory sources, which classify adverse reactions by how often they occur and which body systems they affect.

Frequency-Classified Adverse Reactions

The most commonly reported side effect is diarrhea, classified as Very Common (occurring in ge 1 in 10 patients) in regulatory documents. This typically begins within the first two weeks of treatment.

Common side effects (occurring in ge 1 in 100 to < 1 in 10 patients) include abdominal pain, flatulence (gas), and abdominal distension (swelling).

Uncommon side effects (occurring in ge 1 in 1,000 to < 1 in 100 patients) may include symptoms such as nausea, vomiting, hypokalemia, dehydration, and defecation urgency.

Serious Adverse Reactions and Restrictions

Serious Adverse Reactions

Regulatory labeling highlights the risk of Severe Diarrhea, which can lead to serious dehydration and significant electrolyte imbalances (such as hypokalemia), sometimes requiring intravenous treatment or hospitalization. If severe diarrhea occurs, treatment must be suspended.

Post-marketing reports also include cases of serious Hypersensitivity Reactions and, rarely, intestinal perforation, which is generally associated with localized weakness of the intestinal wall.

Contraindications

Linzess is formally Contraindicated in two key situations:

  1. Pediatric Patients Less Than 2 Years of Age due to the risk of serious dehydration, a statement mandated by the FDA Boxed Warning.
  2. Patients with known or suspected mechanical gastrointestinal obstruction.

Population-Specific Safety Notes

The medicine is generally intended for adult use. Due to the lack of sufficient data on infants and children, it is generally contraindicated for use in patients under 6 years of age. For pregnant or breastfeeding individuals, systemic absorption is negligible; however, caution is advised due to limited human data.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Linaclotide (Linzess) indicates that an overdose is likely to result from an exaggeration of the known pharmacodynamic effects. The primary manifestation documented is diarrhoea.


Documented Overdose Presentations

Classification Manifestation/Outcome
Primary Symptom Diarrhoea (Exaggerated effect)
Serious Outcomes Dehydration, Electrolyte Abnormalities (Hypokalemia, Hyponatremia), Hypotension, Syncope
Pediatric Risk Serious dehydration and death (in nonclinical studies for children under 2 years)

Required Emergency Actions

Management of an overdose relies on supportive measures and symptomatic treatment, as no specific antidote is known. The regulatory labeling instructs that dosing must be stopped if severe diarrhoea occurs.

Immediate medical help must be sought if a patient experiences severe, persistent, or worsening abdominal pain, or signs of severe dehydration, which may necessitate hospitalization and intravenous fluid administration to correct electrolyte imbalances.

Overdose Profile Summary

The overdose profile is defined by the severe consequences of fluid loss. The most severe warning concerns pediatric patients less than 2 years of age, for whom the medicine is contraindicated due to the high risk of life-threatening dehydration. This information is strictly based on the official FDA and EMA regulatory documentation for Linaclotide.

Therapeutic Uses of Linzess

Quick Facts: Therapeutic Domains

  • Adults: Used to manage symptoms associated with Irritable Bowel Syndrome with Constipation (IBS-C) and Chronic Idiopathic Constipation (CIC).
  • Pediatric Patients (Ages 6–17): Used to address Functional Constipation (FC).

What Linzess Treats: Main Uses and Benefits

Linzess (linaclotide) is a medication that may be prescribed by a healthcare provider for the management of specific gastrointestinal conditions. The medicine is indicated for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in adults, a chronic condition characterized by abdominal pain and bowel irregularities.

It is also approved to address Chronic Idiopathic Constipation (CIC) in adults. CIC is defined as persistent or recurrent constipation for which no underlying organic cause can be found. The medication is intended to improve the frequency of spontaneous bowel movements and overall abdominal symptoms in adult patients with these conditions.

Furthermore, Linzess is utilized in pediatric patients aged 6 to 17 for the management of Functional Constipation (FC). The therapeutic goal of treatment is to lessen the severity of the constipation symptoms associated with these chronic disorders and support improved bowel regularity.

Eligibility and Restrictions for Use

Linzess (linaclotide) eligibility is strictly defined by regulatory authorities based on age, specific physical conditions, and certain physiological states.

Contraindications and Exclusions

Classification Population or Condition Regulatory Basis
Contraindicated Patients less than 2 years of age US FDA (Risk of serious dehydration)
Contraindicated Known or suspected mechanical gastrointestinal obstruction US FDA, EMA
Avoid Use Pediatric patients 2 years to less than 6 years of age US FDA (Safety not established)

Approved and Conditional Eligibility

Age and Indication: Use is approved for adults (age 18 and older) for both IBS-C and CIC. In the US, it is also approved for pediatric patients aged 6 to 17 years for Functional Constipation and 7 to 17 years for IBS-C. The European Medicines Agency (EMA) generally recommends avoiding use in patients under 18 years, citing that safety has not been established in this age group.

Comorbid Conditions: No dose adjustments are required for patients with renal impairment or hepatic impairment as the medicine is minimally absorbed. However, use may be restricted or not recommended in patients with chronic inflammatory intestinal conditions (EMA) or those prone to severe water/electrolyte imbalances.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Linzess (linaclotide) has a minimal potential for systemic drug interactions because it is a locally-acting polypeptide and has negligible systemic exposure.

Pharmacokinetic Interactions (PK)

Official regulatory documents state that linaclotide and its active metabolite are not detectable in plasma at therapeutic doses. For this reason, co-administered medicines are not expected to alter the systemic exposure of linaclotide, and linaclotide is not expected to interact with the cytochrome P450 enzyme system or major drug transporters to alter the exposure of other systemic medicines.

Pharmacodynamic Interactions (PD) and Restrictions

The most significant documented interaction is a pharmacodynamic interaction with food. Taking the capsule immediately after a high-fat meal results in an increase in stool frequency and stool looseness. This mandates a timing-based rule for administration: the medicine must be taken at least 30 minutes prior to the first meal of the day.

Co-administration with other oral medicinal products that cause diarrhea or fluid loss may result in an additive pharmacodynamic effect, increasing the risk or severity of dehydration. Furthermore, in cases of severe linaclotide-induced diarrhea, there is a risk of reduced absorption and efficacy for co-administered oral medicines with a narrow therapeutic index.

Mechanism of Action

GC-C Receptor Activation and Fluid Modulation

Linaclotide is a synthetic peptide that acts as a selective agonist for the Guanylate Cyclase-C (GC-C) receptor on the surface of intestinal epithelial cells. This targeted binding triggers a molecular cascade that increases intracellular cyclic Guanosine Monophosphate (cGMP), leading to the opening of the CFTR ion channel. This mechanism promotes the secretion of chloride ( Cl^-) and bicarbonate ( HCO3^-) ions and water into the intestinal lumen, which contributes to the acceleration of intestinal transit.

Visceral Anti-Nociception and Sensation Dampening

The primary mechanism has a second, distinct function: some of the cGMP is released outside the cell (extracellular cGMP), where it modulates the activity of colonic nociceptors (pain-sensing nerves) located in the submucosa. By inhibiting these peripheral nerves, the drug reduces the neural transmission of visceral sensation. This mechanism involves the simultaneous regulation of fluid dynamics and modulation of visceral sensation signaling.

Mechanistic Constraints

The drug's mechanism is peripheral, characterized by minimal systemic absorption. Its fluid-secreting action is highly constrained by the physical presence of a gastrointestinal obstruction. Furthermore, the GC-C receptor is naturally over-expressed in infants, resulting in an exaggerated secretory response in this population.

Dosage and Administration Information

Administration follows protocols focusing on the route, frequency, and relationship to food.

Official Administration Guidelines

Linzess is administered orally and is taken once daily. A key procedural requirement is the timing of the dose: it is consumed on an empty stomach, specifically at least 30 minutes prior to the first meal of the day.

Standard Labeled Dosing Regimens

Dosing is determined by the specific approved condition and population:

Indication Population Recommended Daily Dosage
IBS-C Adults 290 mcg
CIC Adults 145 mcg (or 72 mcg based on patient needs)
Functional Constipation Pediatric (6–17 years) 72 mcg

Administration Procedural Conditions

The hard capsule should be swallowed whole and should not be crushed or chewed, a restriction related to its formulation. For patients unable to swallow the capsule, the contents (beads) may be administered by opening the capsule and mixing the beads with water or applesauce, or via nasogastric/gastrostomy tube; this alternative administration is intended to be completed immediately.

Regarding the overall use pattern, treatment is often maintained long-term for chronic conditions, though the need for continued use is periodically assessed. For example, clinical protocols suggest re-evaluating treatment if no symptom improvement is noted after four weeks. In cases of a missed dose, the standard protocol involves skipping that dose and take the next dose at the regular scheduled time, without taking two doses together. No dose adjustment is required for patients with renal or hepatic impairment.

Recent Clinical Evidence

Linzess (Linaclotide): Recent Clinical Evidence

Linzess is approved for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) and Chronic Idiopathic Constipation (CIC) in adults. It is also approved for Functional Constipation (FC) in pediatric patients aged 6 to 17 years. The drug works by binding to and activating the guanylate cyclase-C (GC-C) receptor in the intestine, which is thought to lead to increased fluid secretion and accelerated intestinal transit.


Clinical Trials in Adults (IBS-C and CIC)

Multiple randomized, double-blind, placebo-controlled Phase III trials established the use of Linzess in adults. These studies evaluated changes in bowel movement frequency and abdominal symptoms over a 12-week period. For adults with IBS-C, the primary endpoint in key trials was often a combined responder definition, requiring specific improvements in both abdominal pain and complete spontaneous bowel movements (CSBMs) simultaneously for a defined number of weeks.

Indication Dosage Strengths Used in Trials
IBS-C (Adults) 290 mcg
CIC (Adults) 145 mcg and 72 mcg

In both the IBS-C and CIC adult trials, improvement in CSBM frequency and abdominal symptoms was often observed within the first week of treatment and maintained throughout the study period.


Pediatric Research

Clinical data, supported by extrapolation of efficacy from adult studies, led to the drug's approval for FC in pediatric patients aged 6 to 17. A 12-week, placebo-controlled trial in this population evaluated the change from baseline in the weekly spontaneous bowel movement (SBM) frequency rate. In this trial, the most commonly reported side effect was diarrhea. Due to the risk of serious dehydration, the drug is contraindicated in pediatric patients under two years of age.

Frequently Asked Questions (FAQ)

Common questions about Linzess (FAQ)


Q: How long does it usually take before I can expect Linzess to start working?

Studies and official information indicate that improvement in bowel movement frequency is often observed within the first week of starting treatment. While individual response may vary, this quick observation of a change is a pattern noted in clinical trials.

Q: What does official guidance say about using Linzess during pregnancy?

Linzess and its active component have negligible systemic absorption, meaning maternal use is generally not expected to result in fetal exposure. However, regulatory documents state there is insufficient human data to definitively assess any drug-associated risk during pregnancy. Use during this time requires consideration by a healthcare provider.

Q: What is the difference between Linzess and other drugs for chronic constipation?

Linzess is classified as a Guanylate Cyclase-C (GC-C) agonist. This means it works by activating a specific receptor in the intestines, which increases fluid secretion and accelerates movement through the gut. This is a different mechanism than older types of constipation treatments, such as osmotic or stimulant laxatives.

Q: What is the maximum amount of time someone is typically prescribed to take Linzess?

Linzess is approved for the treatment of chronic conditions, such as IBS with constipation and chronic idiopathic constipation. The official prescribing information does not specify a maximum duration of use. The need for continued treatment is typically monitored and determined by the healthcare provider through periodic assessment.

Q: What are the long-term effects of taking Linzess as described in medical studies?

Linzess is often used for long-term management of chronic conditions. The most common and most serious ongoing adverse reaction reported in clinical trials and post-marketing surveillance is diarrhea. This side effect can sometimes be severe and lead to dehydration or electrolyte problems, which has been noted to require discontinuation of the drug in some cases.

Q: Can Linzess be taken at the same time as common vitamins or supplements?

No systemic drug-drug interactions are anticipated because Linzess is minimally absorbed into the bloodstream. However, diarrhea is the most common side effect of Linzess, and this diarrhea may potentially reduce the absorption and effectiveness of other oral medications, including vitamins or supplements.

Q: Is Linzess suitable for use in older adults?

Clinical studies included older adults (65 years and older), and no overall differences in safety or effectiveness were observed when compared to younger adult patients. However, the official prescribing information cautions that greater sensitivity of some older individuals to the drug's effects cannot be ruled out.

Q: Does Linzess have any known interactions with over-the-counter pain medications?

Due to Linzess's negligible absorption, no specific systemic drug interactions are expected with most pain medications. However, the official product information notes that the risk of diarrhea is a factor when co-administering with any other medications that may also cause loose stools.

Q: Is there a risk of becoming dependent on Linzess over time?

Linzess is not classified as a controlled substance by regulatory agencies. Its mechanism of action is limited to a local effect within the gastrointestinal tract. Studies and official information indicate that there is no known risk of drug dependence.

Q: Can taking Linzess affect my energy level or cause fatigue?

Fatigue is not listed as a direct, frequent side effect in regulatory documents. Severe diarrhea, if it occurs, has been associated with dehydration and electrolyte imbalance, which may cause related symptoms such as dizziness or fatigue.

Q: Is Linzess available in a generic version?

Linaclotide, the active ingredient, is currently available only as the brand-name medication, Linzess. As of the current regulatory filing status, a generic version of the drug has not yet been approved or marketed.

Q: Are headaches a commonly reported side effect when using Linzess?

Headache is listed in the official adverse reactions section based on clinical trial experience. While not the most frequent side effect, regulatory data indicates it was reported in a small percentage of patients during studies.

Q: Does Linzess interact with heartburn or acid reflux medications?

Regulatory documentation lists Gastroesophageal Reflux Disease (GERD), commonly known as acid reflux, as an adverse reaction that was reported in clinical trials. The prescribing information does not list a specific drug-drug interaction with most common acid reflux medications.

Q: Does Linzess have any interactions with common antibiotics?

No systemic drug-drug interactions are anticipated because the medicine is minimally absorbed. However, the diarrhea caused by Linzess, which is its most common side effect, may potentially reduce the absorption and effectiveness of any other oral medications, including oral antibiotics.

Q: Does Linzess interact with birth control pills?

Official patient counseling information emphasizes that the diarrhea that may occur with Linzess can reduce the absorption and effectiveness of oral contraceptives (birth control pills). This is due to the accelerated transit through the digestive system.

How should Linzess be stored and disposed of?

How to Store and Dispose of Linzess

Linzess (linaclotide) capsules must be stored according to specific conditions to maintain product stability and safety, as defined by regulatory labeling.

Official Storage Conditions

Storage Requirement Specification
Temperature Controlled Room Temperature: 25°C (77°F)
Permitted Range 15°C to 30°C (59°F to 86°F)
Protection Must be protected from moisture

Handling and Disposal

The medication must remain in its original container, which must be kept tightly closed in a dry place. The desiccant packet inside the bottle is required for moisture protection and must not be removed. Linzess and all medicines must be stored out of the reach of children due to the specific risk of accidental overdose. Unused or expired capsules should be disposed of in accordance with local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Linzess found in:

A-Z Index: